Levodopa/Benserazide Orifarm

Levodopa/Benserazide, the active ingredient in Levodopa/Benserazide Orifarm, is an Antiparkinson agent presented as an oral tablet for oral use. It is indicated for the management of Parkinson's disease in adult patients, helping to alleviate motor symptoms by restoring central dopamine levels through the brain's dopaminergic pathways.

GNH USA supplies Levodopa/Benserazide Orifarm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing rigorous quality assurance, regulatory support and customized logistics to meet diverse market requirements throughout the diverse market requirements.

Levodopa/Benserazide is used in the management of Parkinsonian disorders, targeting dopamine deficiency to improve motor function.

- Parkinson's disease: reduces bradykinesia, rigidity and tremor, improving daily motor activities. - Drug‑induced Parkinsonism: restores dopaminergic tone when dopamine antagonists cause motor impairment. - Idiopathic Parkinsonism: helps control early‑stage motor symptoms and delays functional decline. - Secondary Parkinsonian syndrome (vascular): alleviates motor deficits associated with cerebrovascular disease. - Advanced Parkinson's disease with motor fluctuations: provides smoother dopaminergic stimulation when combined with adjunct therapies.

Levodopa/Benserazide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Headache: transient and usually self‑limiting. - Insomnia: difficulty initiating or maintaining sleep. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Dyskinesia: involuntary, erratic movements that may be disabling. - Psychosis or hallucinations: visual or auditory disturbances, especially in older patients. - Severe hypotension: can lead to syncope or falls. - Neuroleptic malignant syndrome: rare but life‑threatening reaction. - Anaphylactic reaction: acute allergic response requiring emergency care.

Levodopa/Benserazide requires careful monitoring in several clinical situations.

- Renal impairment: monitor renal function and adjust therapy as needed. - Cardiovascular disease: observe for orthostatic hypotension and arrhythmias. - Psychiatric history: watch for hallucinations or worsening psychosis. - Concomitant MAO inhibitors: avoid co‑administration due to hypertensive risk. - Pregnancy and lactation: safety not established; use only if benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Levodopa/Benserazide can interact with several medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic drugs: may reduce levodopa efficacy. - Iron or calcium supplements: decrease levodopa absorption. - High‑protein meals: compete with levodopa transport across the gut.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase central levodopa levels. - Antihypertensive agents: additive hypotensive effect. - SSRIs or SNRIs: monitor for serotonin syndrome. - Diuretics: potential electrolyte disturbances affecting blood pressure.